ArticleBJC reports2025

CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumours.

J Randolph Hecht et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.